Education
About Us
Working with TipRanks
Follow Us
Astrana Health Inc. (ASTH)
NASDAQ:ASTH
ASTH Analyst Ratings
Moderate Buy
4 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ASTH Stock 12 Month Forecast
Average Price Target
$32.67
▼(-0.97% Downside)
| Highest Price Target$37.00 | Average Price Target$32.67 | Lowest Price Target$26.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Truist Financial
―
Buy
―
Reiterated
12/15/25
Needham
$28
Buy
-15.13%
Downside
Initiated
12/12/25
Astrana Health Positioned for Aggressive Growth and Valuation Upside Amidst Strong Financials and Market OpportunitiesWe are initiating coverage of Astrana Health (ASTH) with a Buy rating, $28 PT. We believe VBC performance is at an inflection point, with higher reimbursement rates and heightened utilization working their way into benchmarks and ASTH is leaning into full risk deals at a greater rate than others in our coverage. In our view, the shift to risk, as well as organic growth opps in core & emerging markets, can underwrite 20%-30%+ growth LT. This dovetails with a care model that has outperformed in a difficult macro, implying EBITDA margin expansion beyond MSDs as the environment improves in the NT. However, shares trade at ~6x '26 EBITDA, below hospital operators, which we view as a relative floor; we initiate with a Buy as we believe shares should trade at parity or better given the superior financial profile and prospect for catalysts.
Jefferies
$44→$37
Buy
12.16%
Upside
Reiterated
11/25/25
Barclays
$36→$26
Hold
-21.19%
Downside
Reiterated
11/21/25
KeyBanc
―
Hold
―
Reiterated
11/10/25
TD Cowen
$40→$35
Buy
6.09%
Upside
Reiterated
11/10/25
Bank of America Securities
―
Buy
―
Reiterated
11/07/25
William Blair
―
Buy
―
Reiterated
11/07/25
BTIG
$50
Buy
51.56%
Upside
Reiterated
08/10/25
Astrana Health: Strong Financial Performance and Strategic Growth Drive Buy RatingWe expect ASTH to get below 2.5x over the next 12-18 months and ultimately below 2x. Prospect should add at least ~$81M in EBITDA, with another ~$12-$15M in synergies from operational G&A improvements over time. and revenue growth seem high, and we like ASTH's control over the data and medical trend.
Lake Street
$70
Buy
112.19%
Upside
Reiterated
05/09/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Truist Financial
―
Buy
―
Reiterated
12/15/25
Needham
$28
Buy
-15.13%
Downside
Initiated
12/12/25
Astrana Health Positioned for Aggressive Growth and Valuation Upside Amidst Strong Financials and Market OpportunitiesWe are initiating coverage of Astrana Health (ASTH) with a Buy rating, $28 PT. We believe VBC performance is at an inflection point, with higher reimbursement rates and heightened utilization working their way into benchmarks and ASTH is leaning into full risk deals at a greater rate than others in our coverage. In our view, the shift to risk, as well as organic growth opps in core & emerging markets, can underwrite 20%-30%+ growth LT. This dovetails with a care model that has outperformed in a difficult macro, implying EBITDA margin expansion beyond MSDs as the environment improves in the NT. However, shares trade at ~6x '26 EBITDA, below hospital operators, which we view as a relative floor; we initiate with a Buy as we believe shares should trade at parity or better given the superior financial profile and prospect for catalysts.
Jefferies
$44→$37
Buy
12.16%
Upside
Reiterated
11/25/25
Barclays
$36→$26
Hold
-21.19%
Downside
Reiterated
11/21/25
KeyBanc
―
Hold
―
Reiterated
11/10/25
TD Cowen
$40→$35
Buy
6.09%
Upside
Reiterated
11/10/25
Bank of America Securities
―
Buy
―
Reiterated
11/07/25
William Blair
―
Buy
―
Reiterated
11/07/25
BTIG
$50
Buy
51.56%
Upside
Reiterated
08/10/25
Astrana Health: Strong Financial Performance and Strategic Growth Drive Buy RatingWe expect ASTH to get below 2.5x over the next 12-18 months and ultimately below 2x. Prospect should add at least ~$81M in EBITDA, with another ~$12-$15M in synergies from operational G&A improvements over time. and revenue growth seem high, and we like ASTH's control over the data and medical trend.
Lake Street
$70
Buy
112.19%
Upside
Reiterated
05/09/25
Best Analysts Covering Astrana Health
1 Month
xxx
Success Rate
6/9 ratings generated profit
Average Return
+5.57%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +5.57% per trade.
3 Months
xxx
Success Rate
6/9 ratings generated profit
Average Return
+0.21%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +0.21% per trade.
1 Year
Success Rate
3/9 ratings generated profit
Average Return
-0.68%
reiterated a buy rating 4 months ago
Copying David Larsen's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -0.68% per trade.
2 Years
xxx
Success Rate
1/11 ratings generated profit
Average Return
-29.07%
reiterated a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 9.09% of your transactions generating a profit, with an average return of -29.07% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ASTH Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
6
6
1
3
3
Buy
14
13
9
6
7
Hold
1
6
6
10
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
21
25
16
19
16
Each month's total comprises the sum of three months' worth of ratings.
ASTH Financial Forecast
ASTH Stock Forecast FAQ
What is ASTH’s average 12-month price target, according to analysts?
Based on analyst ratings, Astrana Health Inc.’s 12-month average price target is 32.67.
What is ASTH’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for ASTH, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ASTH a Buy, Sell or Hold?
Astrana Health Inc. has a consensus rating of Moderate Buy which is based on 4 buy ratings, 2 hold ratings and 0 sell ratings.
What is Astrana Health Inc.’s price target?
The average price target for Astrana Health Inc. is 32.67. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $37.00 ,the lowest forecast is $26.00. The average price target represents -0.97% Decrease from the current price of $32.99.
The highest analyst price target is $37.00 ,the lowest forecast is $26.00. The average price target represents -0.97% Decrease from the current price of $32.99.
What do analysts say about Astrana Health Inc.?
Astrana Health Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of ASTH?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.